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tIn this issue of TRANSFUSION, Chin-Yee and colleagues report a systematic 
literature review of red blood cell (RBC) transfusion in patients receiving palliative 
care.1  They importantly highlight that while RBC transfusion may provide 
symptomatic relief and subjective improvements to some patients, there is a paucity 
of high-quality evidence at this time to substantively guide or support use of this 
therapy during end-of-life care. Additionally, the risks of RBC transfusion in this 
unwell, diverse patient population are poorly characterized, making the task of 
conducting a proper risk-benefit analysis by ordering providers difficult.   
 
According to the World Health Organization, palliative care is defined as “an 
approach that improves the quality of life of patients and their families facing the 
problem associated with life-threatening illness, through the prevention and relief 
of suffering by means of early identification and impeccable assessment and 
treatment of pain and other problems, physical, psychosocial and spiritual.”2  The 
palliative care population is admittedly a complex and heterogeneous one, with 
different diseases and treatments that can adversely impact hemoglobin levels and 
sense of well-being.  The degree and impact of anemia can be further exacerbated by 
other underlying co-morbidities, nutrition deficiencies and dietary intake; poor 
functional status and deconditioning; and health care setting and support systems 
available to the patient.3  As a consequence, RBC transfusion risks and thresholds 
used in other patient populations are not necessarily applicable in palliative care 
populations.  
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tIdeal evaluations of RBC transfusion in palliative care would incorporate validated 
measures of objective functional changes as well as patient-reported outcomes of 
changes in symptoms, activity, and quality of life.  While RBC transfusion seeks to 
directly address only a subset of the problems that face those receiving palliative 
care, namely those findings related to symptomatic anemia, improvements might 
enable patient enhancements in other areas of their lives.  As documented by Chin-
Yee and colleagues, high-quality studies assessing patient-reported outcomes that 
would capture such direct and indirect benefits of RBC transfusion are lacking. The 
absence of randomized controlled trials regarding the benefits of blood transfusion 
in this population has been noted by others.4,5   
 
Another issue for consideration is the availability and allocation of RBCs, a finite 
resource.  Both RBC collections and utilization are decreasing in the U.S. due, in part, 
to increasing adherence to evidence-based transfusion guidelines and restrictive 
transfusion strategies.6,7  The resulting decrease in surplus RBC units may further 
influence the decision to transfuse these patients, due to the need to maintain an 
adequate RBC inventory for emergencies and other patient populations.  While this i 
ethically challenging area in the treatment palliative care patients is not commonly 
considered, it is nonetheless an important issue that should not be ignored, 
particularly if RBCs with unique manipulations or phenotypes are necessary.8,9  At 
the University of Michigan, the impact of blood product support in terminal patients 
is often included by hospital ethicists in their analyses.    
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tIn palliative care, the combination of unclear benefits and risks of RBC transfusion, a 
heterogeneous patient population, and individualized goals of care emphasizes the 
need for higher quality studies in this area.  Given the  all-encompassing definition 
of palliative care, prospective trials in this area should evaluate RBC transfusion not 
only through the lens of traditional provider-assessed outcome measures in 
previously conducted clinical trials,6 but also through the lens of patient-reported 
outcomes.  The goals and indications for RBC transfusion in these individuals are 
different from almost all other patient populations.  However, selection of validated 
measures of provider-assessed and patient-reported outcomes that appropriately 
assess treatment of anemia remains challenging, as does identification of sub-
populations amongst palliative care patients that would be predicted to have a 
benefit from RBC transfusion.   
 
A recent international, multisite, prospective consecutive cohort study of palliative 
care patients with anemia-related symptoms demonstrated that just under half of 
patients had improvement of their worst symptom (most commonly fatigue), and 
only 78% of patients had improvement in any symptom, one week after RBC 
transfusion.10  These patients received a mean of 2 RBC units, which may reflect a 
difference in their hemoglobin requirements and transfusion needs compared to 
stable, non-bleeding patients that are hospitalized.11  After logistic regression, 
however, no baseline factors in these transfused patients were found to be 
associated with improvement in worst symptoms.  Of note, 12% of patients were 
observed to have some sort of harm associated with transfusion, although severity 
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tdeemed to be mild in all cases.  While this study provides further insights into the 
risk-benefit ratio of RBC transfusion in the palliative care setting, additional work is 
necessary to better characterize the risks and benefits of RBC transfusion, as well as 
those sub-populations that would benefit the most from such a therapeutic 
intervention. 
 
In summary, the decision to transfuse RBCs to palliative care patients is a complex 
one.  Benefits of RBC transfusion therapy in accordance with individualized patient 
goals must be weighed against the attendant risks.12  Additionally, ethical 
considerations regarding utilization of a finite resource such as RBCs must be 
considered.  However, the tenets of autonomy, nonmaleficence, and beneficence 
need not conflict with justice.9,13  As investigations continue in this unique area, 
evidence-based improvements of RBC transfusion in palliative care will allow for 
better selection of patients to transfuse that are more likely to have a therapeutic 
benefit, reduction in the adverse reactions, and ultimately amelioration of 
symptoms necessitating transfusion in this multifaceted population. 
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